CO liberated from a carbon monoxide-releasing molecule exerts a positive inotropic effect in doxorubicin-induced cardiomyopathy

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 2, 2010, Pages 168-175

  Musameh, Muntaser D ^a,b   Green, Colin J ^b   Mann, Brian E ^c   Motterlini, Roberto ^b,d   Fuller, Barry J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NORTHWICK PARK INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Cardiomyopathy; CORM 3; Dobutamine; Inotropic

Indexed keywords

CARBON MONOXIDE RELEASING MOLECULE 3; DOBUTAMINE; DOXORUBICIN; INOTROPIC AGENT; UNCLASSIFIED DRUG; CARBON MONOXIDE; CARDIOTONIC AGENT; CARDIOTOXIN; ORGANOMETALLIC COMPOUND; TRICARBONYLCHLORO(GLYCINATO)RUTHENIUM(II);

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; HEART FUNCTION; HEART RATE; INOTROPISM; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; ANIMAL; CARDIOMYOPATHIES; CHEMICALLY INDUCED; COMPARATIVE STUDY; IN VITRO STUDY; LEWIS RAT; METABOLISM; TOXICITY;

ANIMALS; CARBON MONOXIDE; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CARDIOTOXINS; DOXORUBICIN; IN VITRO TECHNIQUES; MALE; ORGANOMETALLIC COMPOUNDS; RATS; RATS, INBRED LEW;

EID: 77649293826     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181ca4bbc     Document Type: Article

References (50)

1. Sato K, Balla J, Otterbein L, et al. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J Immunol. 2001;166:4185-4194.
2. Motterlini R, Clark JE, Foresti R, et al. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res. 2002;90:E17-E24.
3. Alberto R, Motterlini R. Chemistry and biological activities of COreleasing molecules (CORMs) and transition metal complexes. Dalton Trans. 2007;17:1651-1660.
4. Musameh MD, Fuller BJ, Mann BE, et al. Positive inotropic effects of carbon monoxide-releasing molecules (CO-RMs) in the isolated perfused rat heart. Br J Pharmacol. 2006;149:1104-1112.
5. Clark JE, Naughton P, Shurey S, et al. Cardioprotective actions by a watersoluble carbon monoxide-releasing molecule. Circ Res. 2003;93:E2-E8.
6. Motterlini R. Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activities. Biochem Soc Trans. 2007;35:1142-1146.
7. Klein L. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: Review of trials and practical considerations. Am J Cardiol. 2003;91:F18-F40.
8. Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens. 1995; 8:909-914.
9. Hjalmarson A. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295-1302.
10. Leizorovicz A. Bisoprolol for the treatment of chronic heart failure: A meta-analysis on individual data of two placebo-controlled studies- CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J. 2002;143:301-307.
11. Pitt B. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
12. Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis. 2002;44: 251-266.
13. Patterson JH, Adams KF Jr, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy. 1994;14:514-521.
14. Hampton JR, Van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971-977.
15. Kohmoto J, Nakao A, Kaizu T, et al. Low-dose carbon monoxide inhalation prevents ischemia/reperfusion injury of transplanted rat lung grafts. Surgery. 2006;140:179-185.
16. De Backer O, Elinck E, Blanckaert B, et al. Water-soluble CO-releasing molecules reduce the development of postoperative ileus via modulation of MAPK/HO-1 signalling and reduction of oxidative stress. Gut. 2009; 58:347-356.
17. Otterbein LE. Carbon monoxide: innovative anti-inflammatory properties of an age-old gas molecule. Antioxid Redox Signal. 2002;4:309-319.
18. Brune B, Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol. 1987;32: 497-504.
19. Song R, Mahidhara RS, Liu F, et al. Carbon monoxide inhibits human airway smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Am J Respir Cell Mol Biol. 2002;27:603-610.
20. Liu XM, Chapman GB, Peyton KJ, et al. Carbon monoxide inhibits apoptosis in vascular smooth muscle cells. Cardiovasc Res. 2002;55: 396-405.
21. Sarady JK, Otterbein SL, Liu F, et al. Carbon monoxide modulates endotoxin-induced production of granulocyte macrophage colonystimulating factor in macrophages. Am J Respir Cell Mol Biol. 2002; 27:739-745.
22. Guo Y, Stein AB, Wu WJ, et al. Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol Heart Circ Physiol. 2004;286:H1649-H1653.
23. Engelhardt S, Bohm M, Erdmann E, et al. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: Progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol. 1996;27: 146-154.
24. Lou H, Danelisen I, Singal PK. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. J Mol Cell Cardiol. 2004;36:683-690.
25. Suzuki K, Murtuza B, Suzuki N, et al. Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure. Circulation. 2001;104:I213-I217.
26. Musameh MD, Fuller BJ, Mann BE, et al. Positive inotropic effects of carbon monoxide-releasing molecules (CO-RMs) in the isolated perfused rat heart. Br J Pharmacol. 2006;149:1104-1112.
27. Pouna P, Bonoron-Adele S, Gouverneur G, et al. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol. 1996;117: 1593-1599.
28. Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: Predictiveness and pitfalls. Cell Biol Toxicol. 2007;23:27-37.
29. Zeidan Q, Strauss M, Porras N, et al. Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection. J Submicrosc Cytol Pathol. 2002;34:315-321.
30. Sato M. Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger. J Mol Cell Cardiol. 2004;36:43-48.
31. Ziolo MT.Myocyte nitric oxide synthase 2 contributes to blunted beta-adrenergic response in failing human hearts by decreasing Ca2+ transients. Circulation. 2004;109:1886-1891.
32. Pacher P, Liaudet L, Bai P, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther. 2002;300:862-867. (Pubitemid 34164989)
33. Schwarz ER, Pollick C, Dow J, et al. A small animal model of nonischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res. 1998;39:216-223.
34. Szenczi O, Kemecsei P, Holthuijsen MFJ, et al. Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol. 2005;69:725-732.
35. Musameh MD, Green CJ, Mann BE, et al. Improved myocardial function after cold storage with preservation solution supplemented with a carbon monoxide-releasing molecule (CORM-3). J Heart Lung Transplant. 2007;26:1192-1198.
36. Slinker BK, Wu Y, Green HW, III, et al. Overall cardiac functional effect of positive inotropic drugs with differing effects on relaxation. J Cardiovasc Pharmacol. 2000;36:1-13.
37. Garlid KD, Puddu PE, Pasdois P, et al. Inhibition of cardiac contractility by 5-hydroxydecanoate and tetraphenylphosphonium ion: A possible role of mitoKATP in response to inotropic stress. Am J Physiol Heart Circ Physiol. 2006;291:H152-H160.
38. Felker GM, O'Connor CM. Inotropic therapy for heart failure: An evidence-based approach. Am Heart J. 2001;142:393-401.
39. Cardell LO, Lou YP, Takeyama K, et al. Carbon monoxide, a cyclic GMPrelated messenger, involved in hypoxic bronchodilation in vivo. Pulm Pharmacol Ther. 1998;11:309-315. (Pubitemid 29078056)
40. Foresti R, Hammad J, Clark JE, et al. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. Br J Pharmacol. 2004;142:453-460.
41. Wang YG, Rechenmacher CE, Lipsius SL. Nitric oxide signaling mediates stimulation of L-type Ca2+ current elicited by withdrawal of acetylcholine in cat atrial myocytes. J Gen Physiol. 1998;111:113-125.
42. Langer M, Luttecke D, Schluter KD. Mechanism of the positive contractile effect of nitric oxide on rat ventricular cardiomyocytes with positive force/frequency relationship. Pflugers Arch. 2003;447: 289-297.
43. Hussain AS, Marks GS, Brien JF, et al. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one (ODQ) inhibits relaxation of rabbit aortic rings induced by carbon monoxide, nitric oxide, and glyceryl trinitrate. Can J Physiol Pharmacol. 1997;75: 1034-1037.
44. Sammut IA, Foresti R, Clark JE, et al. Carbon monoxide is a major contributor to the regulation of vascular tone in aortas expressing high levels of haeme oxygenase-1. Br J Pharmacol. 1998;125:1437-1444.
45. Chen KC, McGrath JJ. Response of the isolated heart to carbon monoxide and nitrogen anoxia. Toxicol Appl Pharmacol. 1985;81:363-370.
46. McGrath JJ. The effects of carbon monoxide on the heart: An in vitro study. Pharmacol Biochem Behav. 1984;21(Suppl 1):99-102.
47. Patel AP, Moody AJ, Sneyd JR, et al. Carbon monoxide exposure in rat heart: evidence for two modes of toxicity. Biochem Biophys Res Commun. 2004;321:241-246.
48. Foresti R, Bani-Hani MG, Motterlini R. Use of carbon monoxide as a therapeutic agent: Promises and challenges. Intensive Care Med. 2008; 34:649-658.
49. Motterlini R, Mann BE, Foresti R. Therapeutic applications of carbon monoxide-releasing molecules. Expert Opin Investig Drugs. 2005;14: 1305-1318.
50. Stagni E, Privitera MG, Bucolo C, et al. A water-soluble carbon monoxide-releasing molecule (CORM-3) lowers intraocular pressure in rabbits. Br J Ophthalmol. 2009;93:254-257.